Takara Bio Inc. (TYO:4974)
867.00
-15.00 (-1.70%)
Feb 27, 2025, 3:30 PM JST
Takara Bio Revenue
Takara Bio had revenue of 9.52B JPY in the quarter ending December 31, 2024, a decrease of -10.30%. This brings the company's revenue in the last twelve months to 43.05B, down -9.69% year-over-year. In the fiscal year ending March 31, 2024, Takara Bio had annual revenue of 43.51B, down -44.33%.
Revenue (ttm)
43.05B
Revenue Growth
-9.69%
P/S Ratio
2.36
Revenue / Employee
23.42M
Employees
1,838
Market Cap
101.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 43.51B | -34.64B | -44.33% |
Mar 31, 2023 | 78.14B | 10.44B | 15.43% |
Mar 31, 2022 | 67.70B | 21.61B | 46.90% |
Mar 31, 2021 | 46.09B | 11.52B | 33.33% |
Mar 31, 2020 | 34.57B | -1.28B | -3.56% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,170.61B |
Takeda Pharmaceutical Company | 4,579.02B |
Daiichi Sankyo Company | 1,795.99B |
HOYA Corporation | 837.44B |
Otsuka Holdings | 2,329.86B |
Terumo | 1,011.15B |
Astellas Pharma | 1,867.63B |
Olympus | 993.33B |